In the continuous-fingolimod groups , ARR was lower ( p < 0.0001 ) , BVL was reduced ( p < 0.05 ) , and proportionately more patients were free from 3-month CDP ( p < 0.05 ) than in a group comprising all placebo-fingolimod patients .